In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

The Killip classification in prediction of laboratory efficacy Of P2Y12 receptor inhibitors in patients with STE myocardial infarction

Session Poster session 1

Speaker Zuzana Motovska

Event : ESC Congress 2015

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Antiplatelet Agents
  • Session type : Poster Session

Authors : Z Motovska (Prague,CZ), J Knot (Prague,CZ), M Ondrakova (Prague,CZ), J Ulman (Prague,CZ), F Bednar (Prague,CZ), M Maly (Prague,CZ), P Widimsky (Prague,CZ)

Authors:
Z. Motovska1 , J. Knot1 , M. Ondrakova1 , J. Ulman1 , F. Bednar1 , M. Maly2 , P. Widimsky1 , 1Charles University Prague, 3rd Faculty of Medicine, Faculty Hospital Kralovske Vinohrady - Prague - Czech Republic , 2National Institute of Public Health - Prague - Czech Republic ,

Citation:
European Heart Journal ( 2015 ) 36 ( Abstract Supplement ), 70

Background: High-risk patients with STE myocardial infarction (STEMI) and cardiogenic shock were excluded from large-scale randomized studies (PLATO, TRITON) comparing clinical efficacy and safety of oral P2Y12 inhibitors.

Purpose: The study aimed to investigate impact of Killip classification on laboratory efficacy of P2Y12 inhibitors in patients with STEMI treated with primary PCI.

Methods: 429 patients with STEMI and detailed data on Killip class at presentation, who were included in the LAPCOR (Laboratory AntiPlatelet efficacy and Clinical Outcome Registry; ClinicalTrials.gov NCT02264912) registry, represent the study population. Efficacy of P2Y12 inhibitors was measured by VASP phosphorylation 24±4 hours after a loading dose of clopidogrel (600 mg, N=210), prasugrel (60 mg, N=120), or ticagrelor (180 mg, N=99) and expressed by platelet reactivity index (PRI). High on-treatment platelet reactivity HTPR was defined as PRI≥50%. Laboratory efficacy of P2Y12 inhibitors was compared between patients with (5.2% of study population; age mean (SD) 65.3 (14.8), 36.4% women) and without cardiogenic shock (age 62.5 (12.9), 30.7% women).

Results: Residual platelet reactivity was significantly higher in clopidogrel-treated patients with Killip class 4 in comparison to patients with Killip class <4 (PRI mean (SD) 61.4 (17.2)% vs. 44.4 (22.6)%, P=0.028). The significance of difference was confirmed after correction for baseline confounding characteristics (age, gender, diabetes, hypertension, renal dysfunction) with P value after adjustment=0.013. HTPR was detected in 66.7% of patients with Killip class 4 receiving clopidogrel (vs. 41.4% of Killip <4). No difference in efficacy of ticagrelor was observed between patients with and those without Killip class 4 (PRI mean (SD) 28.2 (14.4) vs. 19.0 (15.6)%, n.s.). All patients with cardiogenic shock initiated on ticagrelor had PRI<50%. In the prasugrel group, residual platelet reactivity was significantly higher in patients with Killip class 4 in comparison to patients with Killip <4 (PRI mean (SD) 35.5 (30.8)% vs. 17.6 (17.6)%, p=0.015. This difference became non-significant after adjusting for confounding variables with P value after adjustment=0.1. The probability to have HTPR in patients initiated on prasugrel with Killip class 4 did not differ significantly from those with Killip class <4 (Odds Ratio 4.6, 95% C.I. 0.8 27.3).

Conclusion: New P2Y12 receptor inhibitors are effective in patients with STEMI irrespective of Killip class at presentation. Clopidogrel should be avoided in this high-risk population, especially in patients with cardiogenic shock.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are